Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study explores the development of a liposomal gel containing andrographolide from the plant Andrographis paniculata to potentially improve psoriasis management by enhancing drug delivery and reducing side effects of conventional treatments.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This case study reports a good response and tolerability for a combination treatment involving high potency topical corticosteroid, minoxidil 2%, LED, and inosine pranobex in a child with alopecia areata.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

This letter to the editor discusses the use of topical cetirizine 1% for treating androgenetic alopecia but reports no new clinical outcomes.

This study found that while hydroxychloroquine was effective and safe for treating alopecia areata, patients using it experienced more relapses compared to those receiving betamethasone.

This case report suggests that crisaborole may be an effective alternative treatment for alopecia areata in pediatric patients, showing significant hair regrowth after two weeks in a 10-year-old girl.

This study found that both topical calcipotriol and narrow band ultraviolet B phototherapy improved hair regrowth and vitamin D3 levels in alopecia areata patients.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This study found that topical application of Serenoa repens extract increased hair count in men with androgenetic alopecia, suggesting it could be an alternative for those unable to use standard medications.

This website listing states that casemedicalresearch.com is available for purchase and aims to offer comprehensive information on various topics, highlighting it as a potential resource.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study developed a low-viscosity triamcinolone acetonide serum, used with a derma stamp microneedling device, to improve targeted treatment of alopecia areata, reporting favorable drug solubility, spreadability, and permeation to hair follicles, while maintaining skin safety.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

This study found that oral cyclosporine therapy was more effective than betamethasone mini-pulse therapy for treating alopecia areata, with a better patient-reported outcome on hair regrowth, despite a higher incidence of mild, reversible adverse effects in the cyclosporine group.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

This study observed that combining targeted UVA phototherapy with topical 8-methoxypsoralen showed cosmetically acceptable hair regrowth in patients with patchy alopecia areata.

This study found that combining a potent steroid with a vitamin D analogue may offer more convenient treatment for localized alopecia areata than using a superpotent steroid alone, with comparable efficacy but fewer side effects.

Using Excimer light with topical steroids is the most effective treatment for alopecia areata.

This study found that the once-daily gel combining calcipotriene and betamethasone dipropionate was more effective and faster in treating scalp psoriasis compared to individual treatments, with a similar safety profile.

This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².

This review explores the detrimental effects of sunlight on the skin’s circadian rhythm and photodamage, noting the potential of natural cosmeceuticals to influence this rhythm, but reports no new results.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

This study found that oral zinc sulphate was effective for treating patchy alopecia areata, with a low relapse rate observed after discontinuing treatment.

This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.